Luu Brendan's Insider Trades & SAST Disclosures
Luu Brendan's most recent trade in Enanta Pharmaceuticals Inc was a trade of 7,500 Common Stock done . Disclosure was reported to the exchange on Feb. 12, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Luu Brendan.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc | Brendan Luu | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,500 | 43,547 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 3,326 | 40,221 (0%) | 0% | 5.6 | 18,592 | Common Stock |
| Enanta Pharmaceuticals Inc | Brendan Luu | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 2,283 | 36,047 (0%) | 0% | 8.1 | 18,401 | Common Stock |
| Enanta Pharmaceuticals Inc | Brendan Luu | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.60 per share. | 01 Dec 2024 | 753 | 38,330 (0%) | 0% | 8.6 | 6,476 | Common Stock |
| Enanta Pharmaceuticals Inc | Luu Brendan | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2024 | 75,000 | 75,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,320 | 40,056 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Luu Brendan | Chief Business Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 973 | 39,083 (0%) | 0% | 12.4 | 12,075 | Common Stock |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,125 | 36,736 (0%) | 0% | 9.6 | 20,464 | Common Stock |
| Enanta Pharmaceuticals Inc | Luu Brendan | Sr. VP, Business Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 753 | 38,861 (0%) | 0% | 9.5 | 7,146 | Common Stock |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 11,360 | 46,030 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 8,945 | 34,670 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 6,416 | 39,614 (0%) | 0% | 52.8 | 338,572 | Common Stock |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 498 | 25,725 (0%) | 0% | 44.3 | 22,076 | Common Stock |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 18,500 | 26,223 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 1,126 | 8,212 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 489 | 7,723 (0%) | 0% | 62.5 | 30,558 | Common Stock |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 286 | 7,086 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 6,800 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Brendan Luu | Sr. VP, Business Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 75,000 | 75,000 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges